nitroglycerin has been researched along with B16 Melanoma in 2 studies
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.
nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Immune escape is a fundamental trait of cancer in which mechanistic knowledge is incomplete." | 1.40 | A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. ( Barsoum, IB; Graham, CH; Siemens, DR; Smallwood, CA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barsoum, IB | 1 |
| Smallwood, CA | 1 |
| Siemens, DR | 1 |
| Graham, CH | 1 |
| Durymanov, MO | 1 |
| Yarutkin, AV | 1 |
| Bagrov, DV | 1 |
| Klinov, DV | 1 |
| Kedrov, AV | 1 |
| Chemeris, NK | 1 |
| Rosenkranz, AA | 1 |
| Sobolev, AS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma[NCT04663126] | Early Phase 1 | 5 participants (Actual) | Interventional | 2021-02-01 | Terminated (stopped due to after inclusion of 5 patients, tracer had low uptake (kidney/liver)) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for nitroglycerin and B16 Melanoma
| Article | Year |
|---|---|
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Topics: Adaptive Immunity; Animals; Apoptosis; B7-H1 Antigen; Cell Line, Tumor; Cytotoxicity, Immunologic; F | 2014 |
Application of vasoactive and matrix-modifying drugs can improve polyplex delivery to tumors upon intravenous administration.
Topics: Administration, Intravenous; Angiotensin II; Animals; Cell Line, Tumor; Collagen Type I; DNA; Drug D | 2016 |